UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~the~~Date ~~Securities~~of ~~Exchange~~Report: December ~~Act~~10, ~~of 1934~~2024

Date of Report (Date of earliest event reported): September 28, 2023

REGENEREX PHARMA, INC.

(Exact name of registrant as specified in its charter)

Nevada	~~000-53230~~	98000-~~0479983~~53230		98-0479983
(State or other jurisdiction of incorporation)	~~(Commission File Number)~~	(~~IRS~~Commission ~~Employer~~File ~~Identification No.~~Number)		(IRS Employer Identification Number)

5348 Vegas Drive, #177Las Vegas, NV	89108
(Address of principal executive offices)	(Zip Code)

5348 Vegas Drive #177

~~Registrant’s~~Las ~~telephone number~~Vegas, ~~including~~NV ~~area code: (877) 761-7479~~89108

~~Not~~(Address ~~Applicable~~of principal executive offices)

(~~Former~~877) 761-7479 Registrant’s ~~name~~telephone ~~or former address~~number, including ifarea ~~changed since last report)~~code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class ~~TradingSymbol~~Trading Symbol (s) Name of each ~~exchangeon~~exchange on which registered ~~N/A~~Common ~~N/A~~RGPX N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.[ ]

~~Item~~SECTION ~~8.01.~~5 ~~Other~~- ~~Events.~~CORPORATE GOVERNANCE AND MANAGEMENT

~~Regenerex~~Item ~~Pharma, Inc~~5.02 ~~Corporate~~Departure ~~and~~of ~~Management~~Directors ~~Structure~~or ~~Update~~Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~2024~~Election ~~Growth~~of ~~Strategy and Product Launch to Reset the Wound Bed Space and Accelerate the Healing Process in Chronic Wounds with 95% Success Rate~~Director

~~Sept~~Effective ~~28,~~December ~~2023- Las Vegas~~6th, ~~NV- Regenerex Pharma~~2024, ~~Inc~~Mr. ~~(OTC: RGPX), announces the establishment of its comprehensive management team and the commencement of the Company manufacturing plans in Q4 2023~~J. ~~Regenerex~~Kenneth ~~Pharma’s~~Hazen ~~products~~has ~~heal~~been ~~wounds~~appointed ~~effectively with its proprietary innovative formulas in the shortest period of time~~ to ~~minimize~~ the ~~chances~~Board of ~~future~~Directors ~~complications. The products have shown to be very effective in healing chronic wounds in multiple clinical evaluations with 95%~~ of ~~wounds~~the ~~demonstrating 100% closure within 90 days~~Company. ~~All of our products feature our proprietary QBx™ ingredients which contribute to setting up a suitable environment to allow wounds to close.~~

~~Currently,~~Mr. ~~there~~Hazen ~~are~~is noa ~~products~~distinguished leader ~~available~~in onthe logistics and supply chain industry, currently serving as the President ~~market~~and ~~that~~CEO ~~are~~of ~~successful~~CTSI-Global. With a B.B.A. in ~~healing~~Marketing ~~chronic~~from the University of Memphis, ~~non-healing~~Hazen ~~wounds~~has ~~through~~been recognized for his exceptional contributions to the ~~down~~field, ~~regulation~~including being one of ~~proteases~~100 graduates chosen to represent the university's "Centennial Class" in 2012. ~~Other~~Under ~~modern~~his leadership, ~~wound~~CTSI-Global ~~dressings~~has received numerous accolades, such as ~~hydrocolloids~~the Top 100 Logistics I.T. Provider and ~~collagens~~Top ~~absorb~~100 ~~wound~~3PL ~~fluids,~~Provider ~~but~~by ~~these~~Inbound ~~dressings~~Logistics23. Hazen's doexpertise ~~not~~is ~~impact~~further ~~the~~highlighted ~~cellular~~by ~~environment~~his ~~with~~involvement ~~simple~~in ~~gauze~~various advisory boards and ~~gauze-like~~professional ~~dressings~~organizations, toincluding ~~cover~~the ~~and~~CSCMP, ~~protect~~the Association for Supply Chain Management, and the ~~wound~~Greater Memphis Chamber.

~~The~~Resignation ~~Company will be manufacturing its complete line~~ of ~~wound~~Certain ~~care~~Directors ~~products~~and ~~from its facility in Memphis, TN~~Officers. ~~Company products include the following:~~

1Effective December 6th, 2024, Ms. ~~Xcellderma™- OTC-~~ ~~Liquid~~Deborah ~~Bandage~~L. Pilant ~~Skin~~resigned ~~Protectant~~her position as Chief Financial Officer, Secretary/Treasurer and Board of Directors of the Company due to her retirement.

~~Xcellderma™~~Appointment products are sterile wound dressings and are effective for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds. During the last several years, a scientific and medical consensus has emerged that elevated protease levels impede wound healing. QBxTM the active ingredient down regulates the production of ~~certain~~Certain ~~proteases and matrix metalloproteases, or MMPs, which are protein enzymes that are proven to impede the healing of a majority of chronic wounds~~Officers. ~~Approximately 80% of chronic wounds display elevated levels of proteases (including MMPs).~~

2Effective December 6th, 2024 Mr. ~~Accelerex- Sterile~~ ~~Wound~~Brent ~~Cream~~Wilson has been appointed to serve as Chief Financial Officer for the Company.

~~The~~Mr. Brent ~~first~~Wilson, ~~commercially~~CPA ~~available~~graduated ~~medical~~cum ~~device,~~laude ~~Accelerex,~~from isMillsaps ~~for~~College ~~the~~in ~~treatment~~1994. He ofhas a30 ~~wide~~years ~~variety~~ of ~~chronic~~experience in accounting and ~~acute~~organizational ~~wounds~~leadership. He ~~Accelerex~~began his isprofessional acareer ~~custom-designed, FDA and CE approved unit-dose, sterile wound dressing impregnated~~ with aninternational ~~ointment~~accounting ~~containing~~firm ~~QBx.~~KPMG ~~Chronic~~where ~~wounds~~he audited ~~are~~public ~~generally defined as wounds that have not healed after thirty days of consistent clinical treatment,~~ and ~~include~~private ~~diabetic~~companies ~~ulcers,~~mainly ~~burns,~~in ~~pressure~~the ~~ulcers (bedsores)~~manufacturing, ~~and~~retail ~~venous stasis ulcers. The Company’s broadly-enabling technology was discovered from oak bark extract~~ and distribution ~~referred to as QBx™~~industries.

3In 2004, Mr. ~~Accelerex- Impregnated~~ ~~Sterile~~Wilson ~~Wound~~began ~~Dressing~~his CFO career and has worked with a diverse range of companies across various industries. His expertise lies in developing and implementing financial strategies that drive growth and increase profitability while mitigating risks. Brent has a proven track record of managing large budgets and investments, leading financial planning and analysis, and overseeing financial reporting and accounting functions.

~~For~~Effective ~~use~~December as6th a2024 ~~wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions~~Dr. ~~FDA-cleared,~~Lee ~~prescription-only~~Ori ~~combination~~has been ~~device~~appointed ~~that~~to ~~blends~~serve ~~the~~as ~~benefits~~Secretary/Treasurer of athe ~~wound~~Company ~~dressing~~for ~~with~~the ~~two drug components~~coming year. ~~Provides 3 modes of action to help treat acute and chronic wounds: Protective dressing, moisturizing ointment and 2 drug components: rubidium chloride and potassium chloride.~~

~~Key~~Dr. ~~Management~~Lee ~~Officers~~Ori ~~and~~is ~~Directors~~a ~~who~~Board ~~will~~of Director beof ~~implementing~~the ~~our growth strategy are as follows:~~Company.

~~About Regenerex Pharma, Inc.~~SIGNATURES

~~Regenerex~~Pursuant ~~Pharma,~~to ~~Inc. provides~~ the requirements ~~most~~of ~~technologically advanced clinically proven products on~~ the ~~market~~Securities ~~today~~Exchange ~~that~~Act ~~successfully~~of ~~heal wounds quicker~~1934, ~~conveniently~~the ~~and~~Registrant ~~cost~~has ~~effectively.~~duly caused ~~Currently,~~this ~~there~~Report ~~are~~to nobe ~~products~~signed ~~available~~ on ~~the~~its ~~market~~behalf ~~that~~by ~~are successful in healing chronic, non-healing wounds through~~ the ~~down regulation of proteases. Other modern wound dressings such as hydrocolloids and collagens absorb wound fluids~~undersigned, ~~but~~hereunto ~~these dressings do not impact the cellular environment with simple gauze and gauze-like dressings to cover and protect the wound~~duly authorized.

We manufacture and market the most efficacious, clinically proven advanced chronic wound care product line in the world. Wounds that don’t heal detract from your quality of life and prevent you from doing things you enjoy. Regenerex’s products provide advanced wound care that can stimulate healing effectively and in shorter period of time compared to traditional methods. Our QBx™ technology contributes to setting up a suitable environment to allow wounds to close. More information about the Company may be found at regenerexpharmainc.com

		REGENEREX PHARMA, INC.

Date: December 10, 2024	By:	/s/ Gregory Pilant
		Gregory Pilant
		Chief Executive Officer

Notice regarding forward-looking statements

This press release contains forward-looking statements that may be subject to various risks and uncertainties. Such forward-looking statements are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and may include statements regarding our future financial performance or results of operations, including expected revenue growth. Unless otherwise required by law, we undertake no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release. Additional information concerning risks and uncertainties that would cause actual results to differ materially from those projected or suggested in the forward-looking statements can be found in the reports that we have filed with the Securities and Exchange Commission.

Contact: Regenerex Pharma, Inc.

Investor Relations Ph: (305) 927-5191

Company Ph: 877-761-RGPX (7479)

Email: investors@regenerexpharmainc.com

regenerexpharmainc.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	REGENEREX PHARMA, INC.
Date: September 28, 2023	By:	/s/ Greg Pilant
		Name: Greg PilantTitle: Chief Executive Officer

Filing Compare · REGENEREX PHARMA, INC.